The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
出版年份 2020 全文链接
标题
The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
作者
关键词
-
出版物
Scientific Reports
Volume 10, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-06-09
DOI
10.1038/s41598-020-66458-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches
- (2019) Dongwei Xu et al. Frontiers in Pharmacology
- Ultrahigh-Throughput Multiplexing and Sequencing of >500-Base-Pair Amplicon Regions on the Illumina HiSeq 2500 Platform
- (2019) Johanna B. Holm et al. mSystems
- Sex Differences in NAFLD : State of the Art and Identification of Research Gaps
- (2019) Amedeo Lonardo et al. HEPATOLOGY
- Update in the classification and the role of intra-arterial stenting in the management of carotid body paragangliomas
- (2019) Sampath Chandra Prasad et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Sex differences in metabolic regulation and diabetes susceptibility
- (2019) Blandine Tramunt et al. DIABETOLOGIA
- Endoplasmic Reticulum stress signaling and the pathogenesis of Non-Alcoholic Fatty Liver Disease
- (2018) Cynthia Lebeaupin et al. JOURNAL OF HEPATOLOGY
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies
- (2018) Andreea-Manuela Mirea et al. TRENDS IN MOLECULAR MEDICINE
- Non-coding RNAs in Various Stages of Liver Disease Leading to Hepatocellular Carcinoma: Differential Expression of miRNAs, piRNAs, lncRNAs, circRNAs, and sno/mt-RNAs
- (2018) Srinivas V. Koduru et al. Scientific Reports
- Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-Analysis
- (2018) Yung Lee et al. Clinical Gastroenterology and Hepatology
- Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
- (2018) Brian N. Finck DIABETES
- A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
- (2018) Divya P. Kumar et al. HEPATOLOGY
- Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis
- (2017) Cristina Alonso et al. GASTROENTEROLOGY
- Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus
- (2017) Kenneth Cusi GUT
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
- (2017) Chris Estes et al. HEPATOLOGY
- Nrf2, the Master Regulator of Anti-Oxidative Responses
- (2017) Sandra Vomund et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
- (2017) Sophie Cazanave et al. Scientific Reports
- Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
- (2017) Yasushi Honda et al. Scientific Reports
- A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
- (2016) Amon Asgharpour et al. JOURNAL OF HEPATOLOGY
- NAFLD and liver transplantation: Current burden and expected challenges
- (2016) Raluca Pais et al. JOURNAL OF HEPATOLOGY
- Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
- (2016) Manoela Mota et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- HPV status is associated with altered PIWI-interacting RNA expression pattern in head and neck cancer
- (2016) Natalie Firmino et al. ORAL ONCOLOGY
- Nonalcoholic fatty liver disease
- (2015) Timothy Hardy et al. CURRENT OPINION IN GASTROENTEROLOGY
- Saroglitazar for the treatment of dyslipidemia in diabetic patients
- (2015) Shashank R Joshi EXPERT OPINION ON PHARMACOTHERAPY
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Enhancing metabolomics research through data mining
- (2015) Ibon Martínez-Arranz et al. Journal of Proteomics
- Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer
- (2015) Lucía Barbier-Torres et al. Oncotarget
- The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients
- (2015) Nasser Aghamohammadzadeh et al. Therapeutic Advances in Endocrinology and Metabolism
- Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
- (2015) Sosale Aravind Sosale et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
- (2013) Jean-Charles Fruchart Cardiovascular Diabetology
- Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
- (2013) Rajendra H. Jani et al. CLINICAL DRUG INVESTIGATION
- Pathophysiology of NASH: Perspectives for a Targeted Treatment
- (2013) Fabio Marra et al. CURRENT PHARMACEUTICAL DESIGN
- A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
- (2013) Rajendrakumar H. Jani et al. Diabetes Technology & Therapeutics
- The global NAFLD epidemic
- (2013) Rohit Loomba et al. Nature Reviews Gastroenterology & Hepatology
- NAFLD, NASH and liver cancer
- (2013) Gregory A. Michelotti et al. Nature Reviews Gastroenterology & Hepatology
- Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression
- (2012) J. Barr et al. JOURNAL OF PROTEOME RESEARCH
- Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
- (2012) Zhaolian Bian et al. Frontiers in Physiology
- Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
- (2011) E. Boettcher et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal
- (2009) Naim Alkhouri et al. Expert Review of Gastroenterology & Hepatology
- A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
- (2008) C. Fernández-Miranda et al. DIGESTIVE AND LIVER DISEASE
- Activation and Dysregulation of the Unfolded Protein Response in Nonalcoholic Fatty Liver Disease
- (2007) Puneet Puri et al. GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started